Brilique Articles
AstraZeneca management shakeup sign of major restructuring leading to stock recovery, say analysts
17 January 2013
STEMI guidelines now recommend AstraZeneca's ticagrelor as first-line treatment option
30 August 2012
US genericization of clopidogrel will initially contract ACS market, before uptake of novel oral agents lifts sector to $2.7 billion
27 August 2012
Brilique first drug to gain post-AMNOG decision in Germany
16 December 2011
AstraZeneca’s blood thinner Brilinta/Brilique demonstrates cost effectiveness; new Nexium indication filed in Japan
24 October 2011
AstraZeneca’s Brilique first to be assessed under Germany’s AMNOG, getting positive view
5 October 2011
AstraZeneca gets UK NICE backing for Brilique; collaborates with PTC for oncology and other potential drugs
30 June 2011
Generic erosion of key high-priced brands will see acute coronary syndrome drug market fall 12% to $809 million in 2016
3 November 2010
Positive CHMP opinions for AstraZeneca and Novartis, but suspension of Octapharma’s Octagam called for; Roche Avastin review
26 September 2010
Showing 1-15 of 15 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
